HOME >> MEDICINE >> NEWS
Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease

FREMONT, Calif., May 18, 1999 -- Abgenix, Inc. (Nasdaq: ABGX) reported today additional results of a Phase II clinical trial of ABX-CBL in graft versus host disease ("GVHD"). ABX-CBL is a proprietary in-licensed mouse antibody that binds to the CBL antigen. The CBL antigen is upregulated on activated immune cells, including T cells, B cells and natural killer cells. The completed trial involved patients in four dose cohorts with severe GVHD, an often fatal side effect of bone marrow transplants ("BMT"). Among patients in the three higher dose cohorts, 56% (10 of 18) survived at least 100 days from the start of treatment with ABX-CBL. This compared favorably to a 22% (2 of 9) survival rate in the low dose cohort. Robert Rivkin, M.D. of the Rocky Mountain Cancer Centers in Denver, Colorado, presented the details of the clinical trial today at the 1999 Annual Meeting of the American Society of Clinical Oncology.

"We believe the survival data reported today strengthens the preliminary safety and response rate data reported earlier," stated R. Scott Greer, president and chief executive officer of Abgenix. "We plan to initiate a pivotal Phase III clinical trial for ABX-CBL as soon as feasible after we have approval from the FDA to proceed."

In March, at the International Bone Marrow Transplant Registry ("IBMTR") meeting, it was reported that, among patients in the three higher dose cohorts, 73% (11 of 15) had a two grade or better improvement in the IBMTR GVHD Severity Scale. This compared favorably to a 25% (2 of 8) response rate in the low dose cohort.

GHVD is a life threatening complication that frequently occurs following an allogeneic BMT. BMTs are used in the treatment of patients with end stage leukemia, certain other serious cancers and immune system disorders. An allogeneic BMT procedure involves transferring marrow, the graft, from a healthy person into an immunosuppressed patient, the host. The transplant is intended to restore nor
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x229
Noonan/Russo Communications
18-May-1999


Page: 1 2

Related medicine news :

1. Melanoma Patients Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports
2. Irritable Bowel Syndrome The Focus Of Three UNC-CH Reports At Digestive Diseases Conference
3. UCSF-Harvard Team Reports Encouraging Results In Drug Study Of Mice With Cancer
4. Bone Marrow With Heart And Lung Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
5. Bone Marrow With Organ Transplants Reduces Rejection Of Transplanted Organs, Reports University Of Pittsburgh
6. BioNumerik Reports Data On Two Novel Supercomputer Engineered Anticancer Agents At 90th Annual Meeting Of The AACR
7. Changes In Levels Of LDLc From Pre- To Post-Menopausal Years Not Valuable Indicator Of Heart Disease, Reports University Of Pittsburgh Researcher
8. Medicare Policy Contradicts Preferred Treatment For Precancerous Skin Conditions, Westwood Squibb Center For Dermatology Research Reports
9. BioNumerik Reports The Supercomputer Supported Discovery Of New, Non-Toxic Chemotherapy Protecting Agent
10. International Study Finds Statins Raise Good Cholesterol, Wake Forest Physician Reports
11. ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/15/2018)... (PRWEB) , ... November 15, 2018 , ... Lisa ... clinical educator for Specialty MED Training will take the stage during the ... December 13-15, 2019. Dr. Vuich is leading a CME workshop hosted by Tailor ...
(Date:11/14/2018)... HERNDON, Va. (PRWEB) , ... November 14, 2018 ... ... Health and Jordan Pisarcik, Vice President, Account Management at DocASAP, will host a ... Nexus” , WHAT:, Hosted by American Medical Group Association (AMGA), the 2018 Institute ...
(Date:11/14/2018)... ... November 14, 2018 , ... For what is a first ... Therapy (EFFT) for Eating Disorders, will present an overview of the EFFT model with ... keynote speakers at the 2019 event. , Next year’s 33rd iaedp™ Symposium is ...
(Date:11/13/2018)... ... November 14, 2018 , ... REMS: Requirements, Regulation, and Enforcement:, ... — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/remsrre ... enforcement tool. A constantly evolving enforcement tool. , In September the FDA added ...
(Date:11/13/2018)... ... 2018 , ... The Centers for Medicare and Medicaid Services ... seven high volume current procedural terminology (CPT) codes as potentially misvalued, amongst which ... RUC (Relative Value Update Committee) of the American Medical Association re-evaluate the work ...
Breaking Medicine News(10 mins):
(Date:11/15/2018)... , ... November 15, 2018 , ... ... in 2016 and is estimated to continue its dominance during the study period. ... Mobile exoskeleton provides mobility to the wearer while augmenting strength to lift heavy ...
(Date:11/15/2018)... ... November 15, 2018 , ... ... its participation in the California Optometric Association’s Monterey Fall Symposium. This three day ... a platform for connecting with hundreds of doctors of optometry. , For this ...
(Date:11/14/2018)... ... November 14, 2018 , ... Planet DDS ... that Hannah Cohen was joining the company as its new Vice President of ... at DaVita, one of the nation’s leading managed care providers. At DaVita, Hannah ...
Breaking Medicine Technology:
Cached News: